Ressources numériques en sciences humaines et sociales OpenEdition Nos plateformes OpenEdition Books OpenEdition Journals Hypothèses Calenda Bibliothèques OpenEdition Freemium Suivez-nous

UK – MHRA approves UK’s first anti-PD-1 monoclonal antibody for treatment of aggressive form of lung cancer

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 20 June 2025, approved serplulimab (Hetronifly) to treat adults with extensive-stage small cell lung cancer (ES-SCLC), which has not previously been treated, and has spread within the lungs or to other parts of the body. 

SCLC is a fast-growing cancer that typically develops in the airways of the lungs. It accounts for 10-15% of lung cancer cases and is often diagnosed at a late stage when the cancer has already spread. 

Serplulimab is a monoclonal antibody (a targeted therapy) that supports the immune system by blocking PD-1, a receptor some cancer cells use to avoid detection. By inhibiting PD-1, it helps immune cells recognise and destroy cancer cells more effectively. 

More information on the MHRA Website.


OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (28 juillet 2025). UK – MHRA approves UK’s first anti-PD-1 monoclonal antibody for treatment of aggressive form of lung cancer. ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/14fys


Vous aimerez aussi...

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

This site uses Akismet to reduce spam. Learn how your comment data is processed.